The stock of Heron Therapeutics Inc. (NASDAQ:HRTX) decreased by -$0.01 on Friday to finish at $1.67, down -0.60 percent. The last five days have seen an average of 1,471,420 shares of common stock traded. 7 times new highs were reached in the current year, with a fall of -$0.8300. The average number of shares traded over the last 20 days was 2,220,780, while the average volume over the last 50 days totaled 2,048,964.
HRTX stock appreciated 8.44% since last month. On 08/15/23, the company’s shares reached a one-month low of $1.3600. The stock touched a high of $5.14 on 01/18/23, after rallying from a low of $1.07 in 52 weeks. The price of HRTX stock has declined by -33.20% or -$0.8300 this year, reaching a new high 7 times. Still, the stock price is down -67.48% from the 52-week high.
Insider Transactions
HRTX stock investors should be aware that Heron Therapeutics Inc. (HRTX) stock had its last reported insider trading activity 38 days ago on Jul 21. On Jul 21, Director Morgan Adam acquired 2,486,744 shares at $1.37 each. This transaction resulted in the insider spending $3,406,839.
Financial Health
For the three months ended June 29, Heron Therapeutics Inc.’s quick ratio was 1.40, while its current ratio was 1.90, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 45.40% percent. Based on annual data, it had gross profit of $52.8 million and revenue of $107.67 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. HRTX’s return on assets (ROA) during the last 12 months has been -57.80%. There was a -107.20% return on investment (ROI) in the past year.
Earnings Surprise
According to Heron Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $31.76 million, while revenues rose by 13.0% to $29.62 million. It was predicted that Heron Therapeutics Inc.’s quarterly earnings would be -$0.35, but it ended up being -$0.23, beating the consensus by -52.20%. EBITDA was -$41.97 million for the quarter. At the end of Heron Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 240.51 million, while its total debt was $156.12 million. Equity owned by shareholders amounts to $140.76 million.
Technical Picture
Here’s a quick look at Heron Therapeutics Inc.’s (HRTX) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 52.95%, suggesting the stock is Neutral, with a 68.08% historical volatility rate.
The stochastic %K and %D were 64.05% and 64.27% respectively, while the average true range (ATR) was 0.1409. Based on the 14-day stochastic reading of 60.78%, the RSI (14) reading is 54.31%. On the 9-day MACD Oscillator, the stock is at 0.0183, and the 14-day reading is at 0.0192.
Analyst Ratings
In its analyst report released on May 27, 2020, Guggenheim began covering Heron Therapeutics Inc. (NASDAQ: HRTX). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Heron Therapeutics Inc. (HRTX) an Buy rating. HRTX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is HRTX’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $10.00, with a median target price of $8.00. In analyzing these forecasts, the average price target given by analysts for Heron Therapeutics Inc. (HRTX) is $7.75.
